GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism.
نویسندگان
چکیده
Glucagon-like peptide-1 (GLP-1) is an endogenous insulinotropic peptide secreted from the gastrointestinal tract in response to food intake. It enhances pancreatic islet beta-cell proliferation and glucose-dependent insulin secretion, and lowers blood glucose and food intake in patients with type 2 diabetes mellitus (T2DM). A long-acting GLP-1 receptor (GLP-1R) agonist, exendin-4 (Ex-4), is the first of this new class of antihyperglycemia drugs approved to treat T2DM. GLP-1Rs are coupled to the cAMP second messenger pathway and, along with pancreatic cells, are expressed within the nervous system of rodents and humans, where receptor activation elicits neurotrophic actions. We detected GLP-1R mRNA expression in both cultured embryonic primary cerebral cortical and ventral mesencephalic (dopaminergic) neurons. These cells are vulnerable to hypoxia- and 6-hydroxydopamine-induced cell death, respectively. We found that GLP-1 and Ex-4 conferred protection in these cells, but not in cells from Glp1r knockout (-/-) mice. Administration of Ex-4 reduced brain damage and improved functional outcome in a transient middle cerebral artery occlusion stroke model. Ex-4 treatment also protected dopaminergic neurons against degeneration, preserved dopamine levels, and improved motor function in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease (PD). Our findings demonstrate that Ex-4 can protect neurons against metabolic and oxidative insults, and they provide preclinical support for the therapeutic potential for Ex-4 in the treatment of stroke and PD.
منابع مشابه
Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease.
Exendin-4 is a naturally occurring more potent and stable analog of glucagon-like peptide-1 (GLP-1) that selectively binds at the GLP-1 receptor. It has been recently demonstrated that GLP-1 receptor stimulation preserves dopaminergic neurons in cellular and rodent models of Parkinson's disease (PD). 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) causes nigrostriatal dopaminergic neurotoxi...
متن کاملResponses of primary somatosensory cortical neurons to controlled mechanical stimulation.
The results of psychophysical studies suggest that displacement velocity may contribute significantly to the sensation of subcortical somatosensory neurons. The cortical correlates of these phenomena, however, are not known. In the present study the responses of rapidly adapting (RA) neurons in the forelimb region of cat primary somatosensory cortex (SI) to controlled displacement of skin and h...
متن کاملEstrogen agonist genistein differentially influences the cognitive and motor disorders in an ovariectomized animal model of Parkinsonism
Objective(s): Parkinson's disease (PD) is a progressive neurological disorder associated with motor disabilities and cognitive dysfunction as well. Evidence indicates that PD occurs less frequently in women than men, confirming a role for steroid hormones in protection of dopaminergic nigrostriatal neurons. It is reported that soy genistein, an estrogen agonist phytoestrogen, display neuroprote...
متن کاملP 12: Study of the Association between Serum Level of Cystatin C and Behavioral Symptoms of 6-Hydroxydopamine – Induced Parkinsonism in Rat
Introduction: Parkinson’s disease (PD) is the second most neurodegenerative disorder which is characterized by a progressive loss of dopaminergic neurons in the substantia nigra pars compacta. Clinical symptoms do not appear until approximately 70% of dopaminergic neurons and 80% of the striatal dopaminergic terminals have been lost. Thus, detecting nonclinical factors such as detecting b...
متن کاملP 13: Correlation Between Alanine Aminotransferase Serum (ALT) Level and Behavioral Symptoms of 6-Hydroxydopamine (6-OHDA)-Induced Parkinsonism in Rats
Introduction: Parkinson disease (PD) is the second frequent human neurodegenerative disease following Alzheimer. This illness is caused by degeneration of dopaminergic neurons in the compact part of substantia nigra (SNpc). Clinical demonstrations are observable when 70% of dopaminergic neurons in SNpc and 80% of dopaminergic terminals in striatum have been degenerated. Characterization of non-...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Proceedings of the National Academy of Sciences of the United States of America
دوره 106 4 شماره
صفحات -
تاریخ انتشار 2009